Last Updated : July 28, 2024
The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Nexavar | Sorafenib tablets | Cancer, Renal cell carcinoma | Do not list | Complete | ||
| Nexavar | Sorafenib | Metastatic Progressive Differentiated Thyroid Carcinoma (DTC) | Do not reimburse | Complete | ||
| Nexplanon | etonogestrel | Prevention of pregnancy | Reimburse with clinical criteria and/or conditions | Complete | ||
| Nexviazyme | avalglucosidase alfa | Pompe disease | Reimburse with clinical criteria and/or conditions | Complete | ||
| Ngenla | somatrogon | Growth hormone deficiency | Reimburse with clinical criteria and/or conditions | Complete | ||
| Ninlaro | Ixazomib | Multiple Myeloma | Do not reimburse | Complete | ||
| Ninlaro | Ixazomib | Multiple Myeloma (2nd-beyond) | Do not reimburse | Complete | ||
| Nitisinone | nitisinone | Hereditary tyrosinemia type 1 | Reimburse with clinical criteria and/or conditions | Complete | ||
| Norprolac | Quinagolide hydrochloride | Hyperprolactinemia | Do not list | Complete | ||
| Norprolac | Quinagolide hydrochloride | Hyperprolactinemia | List with clinical criteria and/or conditions | Complete |
Last Updated : July 28, 2024